PE20140166A1 - Composicion farmaceutica que comprende deferasirox - Google Patents

Composicion farmaceutica que comprende deferasirox

Info

Publication number
PE20140166A1
PE20140166A1 PE2013000646A PE2013000646A PE20140166A1 PE 20140166 A1 PE20140166 A1 PE 20140166A1 PE 2013000646 A PE2013000646 A PE 2013000646A PE 2013000646 A PE2013000646 A PE 2013000646A PE 20140166 A1 PE20140166 A1 PE 20140166A1
Authority
PE
Peru
Prior art keywords
deferasirox
pharmaceutical composition
composition including
agent
polymer
Prior art date
Application number
PE2013000646A
Other languages
English (en)
Spanish (es)
Inventor
Geena Malhotra
Shrinivas Madhukar Dr Purandare
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44802316&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20140166(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of PE20140166A1 publication Critical patent/PE20140166A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE2013000646A 2010-10-01 2011-09-30 Composicion farmaceutica que comprende deferasirox PE20140166A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2750MU2010 2010-10-01

Publications (1)

Publication Number Publication Date
PE20140166A1 true PE20140166A1 (es) 2014-02-17

Family

ID=44802316

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2013000646A PE20140166A1 (es) 2010-10-01 2011-09-30 Composicion farmaceutica que comprende deferasirox
PE2017000227A PE20170468A1 (es) 2010-10-01 2011-09-30 Composicion farmaceutica que comprende deferasirox

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2017000227A PE20170468A1 (es) 2010-10-01 2011-09-30 Composicion farmaceutica que comprende deferasirox

Country Status (18)

Country Link
US (3) US20140147503A1 (enExample)
EP (1) EP2621471A2 (enExample)
JP (1) JP2013538845A (enExample)
KR (1) KR20140011300A (enExample)
CN (1) CN103209687A (enExample)
AP (1) AP3578A (enExample)
AU (1) AU2011309872B2 (enExample)
BR (1) BR112013007276A2 (enExample)
CA (1) CA2812505A1 (enExample)
EC (1) ECSP13012534A (enExample)
IL (1) IL225457A (enExample)
MX (1) MX2013003522A (enExample)
MY (1) MY165826A (enExample)
NZ (1) NZ608380A (enExample)
PE (2) PE20140166A1 (enExample)
RU (1) RU2589842C2 (enExample)
WO (1) WO2012042224A2 (enExample)
ZA (1) ZA201302092B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011326562B2 (en) 2010-11-09 2017-02-23 Cornell University Methods for organ regeneration
EP2916870A1 (en) 2012-11-12 2015-09-16 Cipla Limited Fixed dose pharmaceutical composition comprising deferasirox and deferipone
HUE036921T2 (hu) 2013-03-08 2018-08-28 Novartis Ag Orális deferasirox készítmények
US10646452B2 (en) * 2013-03-15 2020-05-12 New Jersey Institute Of Technology System and method for fabrication of uniform polymer films containing nano and micro particles via continuous drying process
RU2015149544A (ru) * 2013-05-10 2017-06-16 Сипла Лимитед Низкодозовая фармацевтическая композиция
TWI697337B (zh) * 2013-08-07 2020-07-01 學校法人近畿大學 奈米粒子或奈米粒子組成物之製造方法，及支架或球囊導管之製造方法
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
WO2015114314A1 (en) * 2014-01-28 2015-08-06 Cipla Limited Pharmaceutical composition comprising abiraterone
WO2015140569A1 (en) * 2014-03-20 2015-09-24 Cipla Limited Pharmaceutical composition
KR20160088965A (ko) * 2015-01-16 2016-07-27 대원제약주식회사 데페라시록스를 함유하는 현탁제
JP2018517734A (ja) * 2015-06-17 2018-07-05 ディスパーソル テクノロジーズ リミテッド ライアビリティ カンパニー デフェラシロクスの改善された製剤およびその作製方法
KR101695970B1 (ko) * 2015-07-31 2017-01-13 건일제약 주식회사 데페라시록스 함유 산제 및 그 제조방법
CA3029543C (en) * 2016-07-05 2021-11-23 Jubilant Generics Limited Immediate release pharmaceutical composition of iron chelating agents
CN107693516B (zh) * 2016-08-08 2020-06-26 上海宣泰医药科技有限公司 一种地拉罗司药物组合物及其药物制剂、制备方法和用途
EP3518904A1 (en) 2016-09-30 2019-08-07 Synthon B.V. Pharmaceutical composition comprising deferasirox
CA3061267A1 (en) * 2017-04-07 2018-10-11 Maa Laboratories, Inc. Methods of improving the solubility and bioavailability of therapeutic agents
CZ2017255A3 (cs) * 2017-05-04 2018-11-14 Zentiva, K.S. Filmem potažené tablety Deferasiroxu
WO2019108156A1 (en) * 2017-11-28 2019-06-06 Biofarma Ilac Sanayi Ve Ticaret A.S. A scored tablet formulation comprising deferasirox in a film tablet form
WO2020033412A1 (en) * 2018-08-06 2020-02-13 Watt Richard K Compositions and methods for treating iron overload
CN121265577A (zh) 2020-05-18 2026-01-06 奥瑞克索股份公司 用于药物递送的药物组合物
TW202333658A (zh) 2021-11-25 2023-09-01 瑞典商奥瑞克索股份公司 包含腎上腺素之新穎醫藥組合物
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device
CN115154428B (zh) * 2022-09-06 2023-01-10 上海奥科达医药科技股份有限公司 一种地拉罗司药物组合物及其制备方法
CN115400088B (zh) * 2022-09-06 2023-07-07 上海奥科达医药科技股份有限公司 一种地拉罗司药物组合物及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1708343A1 (ru) * 1989-09-22 1992-01-30 Всесоюзный Научно-Исследовательский Институт Биотехнологии Способ получени твердых лекарственных форм
MY129541A (en) * 1996-06-25 2007-04-30 Novartis Ag Substituded 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
US20040033267A1 (en) * 2002-03-20 2004-02-19 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
EP1341521B1 (en) * 2000-11-20 2009-01-07 Elan Pharma International Limited Nanoparticulate compositions comprising a drug and copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
US6509380B1 (en) * 2001-12-14 2003-01-21 Marshall University Research Corporation Method of treating iron overload with acetaminophen
GB0223978D0 (en) 2002-10-15 2002-11-20 Novartis Ag Organic compound
GB0408078D0 (en) 2004-04-08 2004-05-12 Novartis Ag Organic compounds
US7531351B2 (en) * 2004-06-14 2009-05-12 Probiogen Ag Liquid-gas-phase exposure reactor for cell culturing
NZ567155A (en) 2005-10-19 2010-06-25 Novartis Ag Dispersible tablets comprising deferasirox
US20090016359A1 (en) * 2007-07-11 2009-01-15 Samsung Electronics Co., Ltd. System and method for processing high definition video data to be transmitted over a wireless medium
WO2009016359A1 (en) * 2007-07-27 2009-02-05 Pliva Hrvatska D.O.O. New forms of deferasirox
EP2062572A1 (en) 2007-11-19 2009-05-27 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions
EP2291360A2 (en) * 2008-04-21 2011-03-09 Actavis Group PTC ehf. Solid state forms of deferasirox salts and process for the preparation thereof
WO2010035282A1 (en) * 2008-09-24 2010-04-01 Matrix Laboratories Limited Pharmaceutical compositions comprising deferasirox

Also Published As

Publication number Publication date
AU2011309872A1 (en) 2013-04-11
US20160324831A1 (en) 2016-11-10
WO2012042224A3 (en) 2012-08-09
CN103209687A (zh) 2013-07-17
RU2589842C2 (ru) 2016-07-10
KR20140011300A (ko) 2014-01-28
WO2012042224A8 (en) 2013-04-11
US20180311216A1 (en) 2018-11-01
AP3578A (en) 2016-02-08
AP2013006785A0 (en) 2013-04-30
IL225457A0 (en) 2013-06-27
EP2621471A2 (en) 2013-08-07
AU2011309872B2 (en) 2014-09-04
IL225457A (en) 2017-04-30
WO2012042224A2 (en) 2012-04-05
CA2812505A1 (en) 2012-04-05
MX2013003522A (es) 2013-05-22
US20140147503A1 (en) 2014-05-29
ECSP13012534A (es) 2013-10-31
JP2013538845A (ja) 2013-10-17
PE20170468A1 (es) 2017-04-26
MY165826A (en) 2018-05-17
RU2013120275A (ru) 2014-11-20
ZA201302092B (en) 2013-11-27
BR112013007276A2 (pt) 2016-06-14
NZ608380A (en) 2014-10-31

Similar Documents

Publication Publication Date Title
PE20131324A1 (es) Formulacion subcutanea de anticuerpo anti-her2
PE20170468A1 (es) Composicion farmaceutica que comprende deferasirox
PE20120326A1 (es) Formulaciones farmaceuticas para reducir la proliferacion y viabilidad de los agentes microbianos
MX2018012705A (es) Suministro de agente soluble en surfactante.
BR112013031714A2 (pt) composições de cuidados pessoais
PE20121178A1 (es) FORMULACION SUBCUTANEA QUE COMPRENDE EL ANTICUERPO ANTI-CD20: OCRELIZUMAB, OBINUTUZUMAB O RITUXIMAB, Y LA ENZIMA HIALURONIDASA: rHuPH20
EP4427727A3 (en) Compact shampoo composition containing sulfate-free surfactants
MX2019012694A (es) Composiciones con un polimero de espesamiento.
CO6440528A2 (es) Composiciones adyuvantes que comprenden un agente de isotonicidad no iónico.
MX2019008123A (es) Articulo con estructura soluble de trama fibrosa que comprende agentes activos.
PE20142314A1 (es) Composiciones intranasales de dexmedetomidina y metodos de uso de ellas
ECSP088239A (es) Composición de liberación de fármaco sostenida
AR065884A1 (es) Producto de cuidado bucal y metodos de uso del mismo
IN2014CN02592A (enExample)
BR112012014260A2 (pt) composições de iodopovidona oftalmológica não irritante
CO6731078A2 (es) Espumas acuosas contra incendios con contenido reducido de fluor
SA523440384B1 (ar) مركبات الفوسفوليبيدات واستخداماتها
MA38399B2 (fr) Formulation sous forme de comprimé, utile pour traiter l'insuffisance cardiaque aiguë et l'insuffisance cardiaque chronique
PE20121517A1 (es) Compuestos lipopeptidos y metodos relacionados
ECSP088240A (es) Composición de trazodona para administración una vez por día
PE20130045A1 (es) FORMULACIONES INTRAVENOSAS DE COENZIMA Q10 (CoQ10) Y METODOS DE USO DE LAS MISMAS
MX361371B (es) Composición de gel de lavado de peróxido de benzoílo (bpo).
BR112016022340A2 (pt) Composição, uso cosmético de uma composição, medicamento e kit
BR112014019730A8 (pt) Sistema tensoativo estruturado aquoso e composição de cuidado pessoal
AR075063A1 (es) Composiciones que comprenden agentes tensoactivos no ionicos y zwiterionicos

Legal Events

Date Code Title Description
FC Refusal